Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. As of today (2026-09-20), Adia Med's 5-Year Sortino Ratio is 5.35.
Adia Med (OTCPK:ADIA) 5-Year Sortino Ratio Explanation
The 5-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past five year. It is calculated as the annualized result of the average five-year monthly excess returns divided by the standard deviation of negative returns in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.
Adia Med 5-Year Sortino Ratio Related Terms
ADIA vs SYRA, GBCS, AMS: 5-Year Sortino Ratio Comparison
For the Medical Care Facilities subindustry, Adia Med's 5-Year Sortino Ratio, along with its competitors' market caps and 5-Year Sortino Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adia Med 5-Year Sortino Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Adia Med's 5-Year Sortino Ratio distribution charts can be found below:
* The bar in red indicates where Adia Med's 5-Year Sortino Ratio falls into.
The 5-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last five year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 5-Year Sortino Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past five year.
A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.
Adia Med (ADIA) has a 5-Year Sortino Ratio of 5.35 as of Sep. 20, 2026. 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. View historical data for Adia Med and its competitors.
Is Adia Med's 5-Year Sortino Ratio too high?
Adia Med's current 5-Year Sortino Ratio is 5.35. Overall, Adia Med has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Adia Med's 5-Year Sortino Ratio compare to SYRA and GBCS?
Adia Med's 5-Year Sortino Ratio of 5.35 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Sortino Ratio for a Healthcare Providers & Services company?
A good 5-Year Sortino Ratio depends on the Healthcare Providers & Services industry context. However, 5-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Sortino Ratio mean?
A high 5-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. View historical data for Adia Med and its competitors. Adia Med's current 5-Year Sortino Ratio is 5.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adia Med stock overvalued right now?
Adia Med (ADIA) has a current 5-Year Sortino Ratio of 5.35. The current 5-Year Sortino Ratio is 5.35. Adia Med's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Sortino Ratio calculated?
5-Year Sortino Ratio is calculated from a company's financial statements. For Adia Med (ADIA), the current 5-Year Sortino Ratio is 5.35 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adia Nutrition Inc focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Its products and the deployment of the therapies utilizing its products address various orthopedic issues, pain management, and wound repair. In addition, its products are able to be utilized in various other therapies to address anti-aging issues and other tissue repair desires. It operates in three segments The Biolete segment comprises the sale of supplements; Adia Med performs stem cell treatments to patients; and Adia Labs procures and sells stem cell products to outside clinics or to Adia Med. It derives revenue from Sales of supplements, Medical procedures, Sales of biologics and ancillary products.
20GF Score
Get the complete analysis for ADIA
5-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADIA has been successfully added to your 
